Clinical Trials

SARS-CoV-2 antibody after COVID-19 vaccination in patients with multiple sclerosis

Type of Study/Intervention

Prospective cohort study

Recruitment Status


Form of MS

Relapsing remitting MS, Secondary progressive MS, Primary progressive MS, Relapsing MS

Brief summary

COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to determine the COVID-19 vaccine immunogenicity and to assess the protection given by vaccines in people living with MS.

Inclusion criteria

– Diagnosed Multiple Sclerosis according to 2017 McDonald criteria
– Treatment by any TGA-approved Disease Modifying Therapy (DMT) for MS, e.g. ocrelizumab, alemtuzumab, natalizumab, fingolimod, cladribine, beta-interferon, copaxone, dimethylfumarate, ofatumumab, siponimod, glatiramer acetate.
– Recipient of COVID-19 vaccine (Pfizer, Astra Zeneca, or Novavax).
– Is able to give consent

Exclusion criteria

Non-English speaking

Anticipated start date

May 2021

Recruitment contacts

Fabienne Brilot-Turville,



Ethics approval


Last updated


Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search